Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Immunitor Inc.
Street 1: 365 - 2906 West Broadway
Street 2:
City: Vancouver
Post Code:
Country: Canada
Phone: 360-566-2194
Organization Email:
Web Site:
Other Online Presence:

Focal Point Contact Information

Salutation: Dr
First Name: Allen
Last Name: Bain
Title: Director

Alternate Focal Point Contact Information

Salutation: Dr
First Name: Aldar
Last Name: Bourinbaiar
Title: CEO

General Information

Board Constituency: Private sector
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Private Sector
Organization Type - Secondary: Company
Organization Description:
Immunitor develops, manufactures, and clinically validates immunotherapies and therapeutic vaccines for tuberculosis indication including MDR-TB and TB-HIV. Our published clinical trials indicate fast sputum clearance resulting from adjunct immunotherapy. Current focus is an oral M vaccae formulation in Phase 2b clinical trial as a therapeutic vaccine. So far 2 phase trials were conducted. Sputum clearance was seen within one month in about 85% of patients.
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Provision of drugs, diagnostics and commodities
Research and Development

Other Organization Information

Total number of staff in your organization: 6 - 10
Number of full-time staff who are directly involved with TB: 6 - 10
Number of part-time staff who are directly involved with TB: 6 - 10
Number of volunteers who are directly involved with TB: 6 - 10
How did you hear about the Stop TB Partnership: Stop TB communications
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Network with other partners
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
Our primary geographic focus is on countries where TB is highly prevalent, several of which we are already present with our ongoing work.

Geographical Reach

Which country is your headquarters located in: Canada
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Russian Federation
South Africa
United States of America


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB Care Delivery:
We are working to enhance DOTS by using assessing the efficacy and safety of adjunct immunotherapies in association with DOTS drugs.

Drug-Resistant TB:
Our immunotherapies have shown efficacy for drug-resistant TB.

Our immunotherapies have shown efficacy for TB-HIV treatment.

New TB Drugs:
Although immunotherapies are not usually classified as "drugs", their addition to approved drug combination therapies for TB will reduce treatment duration and enhance their efficacy.

New TB Vaccines:
To date, our V5 and V7 products have shown clinical efficacy and safety as treatment vaccines. Current focus is on V7, an oral formulation of M. vaccae.


Declaration of interests:
Immunitor personnel have stock ownership and are thus incentivized.

Application date: October 20, 2011
Last updated: July 29, 2013